Finance

Lists
Why is 000963 up 2.86%?
Dive Deeper
000963:SHE
Huadong Medicine Co., Ltd.
CNÂ¥26.62
+2.86%
(+0.74) 1D
Oct 30, 3:04:03 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 000963...
Open
CNÂ¥25.83
High
CNÂ¥26.86
Low
CNÂ¥25.71
Mkt. cap
46.68B
Avg. vol.
13.36M
Volume
26.70M
Dividend
3.49%
Quarterly dividend
CNÂ¥0.23
Ex-dividend date
Sep 18, 2026
P/E ratio
13.58
52-wk high
CNÂ¥43.78
52-wk low
CNÂ¥25.63
EPS
CNÂ¥1.96
Shares outstanding
1.75B
No. of employees
19K
Open
CNÂ¥25.83
High
CNÂ¥26.86
Low
CNÂ¥25.71
Mkt. cap
46.68B
Avg. vol.
13.36M
Volume
26.70M
Dividend
3.49%
Quarterly dividend
CNÂ¥0.23
Ex-dividend date
Sep 18, 2026
P/E ratio
13.58
52-wk high
CNÂ¥43.78
52-wk low
CNÂ¥25.63
EPS
CNÂ¥1.96
Shares outstanding
1.75B
No. of employees
19K
News stories
From web sources and news partners
Profile
HD Medicine, or Huadong Medicine Co., Ltd., is a Hangzhou-based pharmaceutical company registered on the Shenzhen Stock Exchange since December 1999. It has a listed share capital of 380,000,000 RMB and a market capitalization of 5.1981 billion RMB as of June 2026. It is the largest pharmaceutical company in Zhejiang and the leading immunosuppressant manufacturer in China. In June 2025, the company received approval to commence clinical trials for Roflumilast Foam, targeting dermatological conditions. Wikipedia
About Huadong Medicine Co., Ltd.
CEO-
Employees19.1K
FoundedMar 31, 1993
Headquarters-
SectorHealth care provider
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
10.95B
11.18B
10.88B
10.95B
Cost of goods sold
7.79B
7.39B
7.45B
7.39B
Cost of revenue
7.79B
7.39B
7.45B
7.39B
Research and development expenses
245.56M
350.37M
396.72M
426.04M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.99B
2.19B
1.92B
1.96B
Operating expense
2.51B
2.60B
2.41B
2.35B
Total operating expenses
10.31B
9.99B
9.86B
9.74B
Operating income
642.86M
1.19B
1.03B
1.21B
Other non operating income
53.61M
-4.09M
-10.61M
-123.53M
EBT including unusual items
753.84M
1.19B
1.02B
1.05B
EBT excluding unusual items
723.38M
1.19B
1.01B
1.09B
Income tax expense
84.85M
195.03M
176.07M
141.83M
Effective tax rate
11.26%
16.36%
17.28%
13.50%
Other operating expenses
224.00M
58.88M
63.39M
-6.59M
Net income
666.42M
1.00B
858.57M
911.12M
Net profit margin
6.09%
8.96%
7.89%
8.32%
Earnings per share
-
-
-
-
Interest and investment income
12.97M
20.16M
18.36M
31.21M
Interest expense
-
-19.18M
-12.03M
-38.52M
Net interest expenses
12.97M
979.40K
6.33M
-7.31M
Depreciation and amortization charges
-
-
-
-
EBITDA
873.59M
1.43B
1.29B
1.45B
Gain or loss from assets sale
-2.26M
-
-1.42M
1.42M
Upcoming events
AI content may include mistakes. Learn more
Google apps